Reference | Method | No. of patients | Results | Dose |
---|---|---|---|---|
In vitro stimulation and expansion | ||||
Rooney et al. (1995) [25] | Allogeneic EBV-specific CD8+ T cells | 10 | Therapy: 3/3 responders Prophylaxis: 7/7 virus free | 0.2–1.2 × 108 cells/m2 |
Rooney et al. (1998) [26] | Allogeneic EBV-specific CD8+ T cells | 39 | Prophylaxis: all PTLD free | 0.2–1.0 × 108 cells/m2 |
Haque et al. (2002) [50] | Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase I/II | 8 | 4/8 remission | 106 cells/kg |
Haque et al. (2007) [51] | Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase II | 33 | 14/33 complete remission 3/33 partial response | 2 × 106 cells/kg |
Heslop et al. (2010) [49] | Allogeneic EBV-specific CD8+ T cells | 114 | Therapy: 11/13 complete response prophylaxis: all PTLD free | 1–5 × 107 cells/m2 |
Doubrovina et al. (2012) [63] | Allogeneic EBV-specific CD8+ T cells | 19 | 13/19 complete response | 106 cells/kg |
Gallot et al. (2014) [64] | Allogeneic EBV-specific polyclonal CD8+ and CD4+ T cells phase I/II | 11 | 4/10 responders | 5 × 106 cells/kg |
EBV-specific third-party CD8+ and CD4+ T cells phase I | 1 | 0/1 responded | 1 infusion of 1.37–5.0 × 107 cells/m2 | |
Direct isolation via peptide-HLA multimers | ||||
Uhlin et al. (2010) [65] | Allogeneic EBV-specific CD8+ T cells using MHC-I-pentamers | 1 | 1/1 complete response | 1.1 × 104 cells/kg and 2 × 104 cells/kg |
Direct isolation via cytokine-capture technique | ||||
Moosmann et al. (2010) [66] | EBV-specific polyclonal CD8+ and CD4+ T cells | 6 | 3/6 responders | 0.4–9.7 × 104 cells/kg |
Icheva et al. (2013) [29] | EBV-specific polyclonal CD8+ and CD4+ T cells | 10 | 7/10 responders | 0.15–53.8 × 103 cells/kg |
Kà llay et al. (2018) [43] | EBV-specific polyclonal CD8+ and CD4+ T cells | 2 | 2/2 responders | 1.8–2.3 × 104 cells/kg |